Literature DB >> 3555058

In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.

F H Kayser, J Novak.   

Abstract

A review of European data published before July 1986 and data from the authors' laboratory showed very similar activity of ciprofloxacin against gram-positive bacteria in all studies. Mean minimal inhibitory concentrations against 50 percent (MIC50) and 90 percent (MIC90) of staphylococcal strains were 0.32 and 0.59 mg/liter, respectively. The drug was equally active against staphylococcal strains resistant and susceptible to methicillin and/or gentamicin. The range of MIC50 and MIC90 values for Streptococcus faecalis and Streptococcus faecium was between 0.25 and 1 mg/liter and 1 to 8 mg/liter, respectively. Ciprofloxacin inhibited group A and group B streptococci at concentrations of 0.5 to 2 mg/liter. Group C and G strains were less susceptible (MICs, 2 to 16 mg/liter). Penicillin-resistant and penicillin-susceptible pneumococci and the Viridans streptococci were inhibited by 0.5 to 4 mg/liter. MIC50 and MIC90 values of ciprofloxacin against Corynebacterium, including group JK, and anaerobic gram-positive cocci were 1 and 8 mg/liter, respectively, and against anaerobic gram-positive rods, were 2 and 16 mg/liter, respectively. Listeria monocytogenes strains were inhibited by 0.12 to 2 mg/liter. Ciprofloxacin showed bactericidal activity against staphylococci and streptococci in minimal bactericidal concentration tests and in killing kinetic studies. The in vitro activity of the drug was influenced neither by the method employed, by the medium used, by the pH of the medium, nor by the size of the inoculum. Resistance to ciprofloxacin developed in staphylococci in a step-wise manner. First-step mutants usually showed a fourfold to eightfold decrease in susceptibility. Contrary to the situation in gram-negative organisms, resistant mutants did not show reduced growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3555058

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

2.  Increasing resistance of enterococci to ciprofloxacin.

Authors:  D R Schaberg; W I Dillon; M S Terpenning; K A Robinson; S F Bradley; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 3.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

4.  Treatment of Streptococcus pneumoniae otitis media in a chinchilla model by transtympanic delivery of antibiotics.

Authors:  Rong Yang; Vishakha Sabharwal; Nadya Shlykova; Obiajulu S Okonkwo; Stephen I Pelton; Daniel S Kohane
Journal:  JCI Insight       Date:  2018-10-04

5.  Resorbable ciprofloxacin/polyglycol acid carrier in the local therapy of chronic osteitis.

Authors:  S Winckler; J P Overbeck; R Meffert; P Törmälä; H U Spiegel
Journal:  Eur J Orthop Surg Traumatol       Date:  1995-12

Review 6.  Quinolone disposition in the elderly. Practical implications.

Authors:  I Nilsson-Ehle; B Ljungberg
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

7.  Prevalence of ciprofloxacin resistance in multiresistant gram-negative intensive care unit isolates.

Authors:  C M Khurana; B R Wojack
Journal:  Infection       Date:  1994       Impact factor: 3.553

8.  Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

Authors:  R A Zabinski; K J Walker; A J Larsson; J A Moody; G W Kaatz; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.